SGLT2i用于糖尿病和非糖尿病慢性肾脏病的循证心肾保护:欧洲肾脏病学会EURECA-m与ERBP工作组综合综述
2015年前以血压控制和肾素-血管紧张素系统抑制为主,但ACEI和ARB在CKD大型试验中未减少心血管事件和死亡。SGLT2i临床试验(DAPA-HF、EMPEROR、CREDENCE、DAPA-CKD、EMPA-KIDNEY)显示可降低心衰和肾衰竭进展风险,心肾获益相对尺度在有无糖尿病患者中相似。EURECA-m和ERBP共识总结最新证据和指南。
要点
- ACEI和ARB在CKD大型试验中未减少心血管事件和死亡。
- SGLT2i试验显示降低心衰和肾衰竭进展风险,有无糖尿病获益相似。
核心结论
- SGLT2i在糖尿病和非糖尿病CKD患者中具有心肾保护获益,相对尺度获益相似。
研究设计与样本
- EURECA-m和ERBP工作组的共识论文,综合最新证据并总结SGLT2i用于心肾保护的指南。
主要发现
- 2015年前以血压控制和肾素-血管紧张素系统抑制为主,但ACEI和ARB在CKD大型试验中未减少心血管事件和死亡。
- DAPA-HF、EMPEROR、CREDENCE、DAPA-CKD和EMPA-KIDNEY试验显示SGLT2i降低心衰和肾衰竭进展风险。
- SGLT2i心肾获益相对尺度在有无糖尿病患者中相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic kidney disease (CKD) is a major public health issue affecting an estimated 850 million people globally. The leading causes of CKD is diabetes and hypertension, which together account for >50% of patients with end-stage kidney disease. Progressive CKD leads to the requirement for kidney replacement therapy with transplantation or dialysis. In addition, CKD, is a risk factor for premature cardiovascular disease, particularly from structural heart disease and heart failure (HF). Until 2015, the mainstay of treatment to slow progression of both diabetic and many non-diabetic kidney diseases was blood pressure control and renin-angiotensin system inhibition; however, neither angiotensin-converting enzyme inhibitors (ACEIs) nor angiotensin receptor blockers (ARBs) reduced cardiovascular events and mortality in major trials in CKD. The emergence of cardiovascular and renal benefits observed with sodium-glucose cotransporter-2 inhibitors (SGLT2i) from clinical trials of their use as anti-hyperglycaemic agents has led to a revolution in cardiorenal protection for patients with diabetes. Subsequent clinical trials, notably DAPA-HF, EMPEROR, CREDENCE, DAPA-CKD and EMPA-KIDNEY have demonstrated their benefits in reducing risk of HF and progression to kidney failure in patients with HF and/or CKD. The cardiorenal benefits-on a relative scale-appear similar in patients with or without diabetes. Specialty societies' guidelines are continually adapting as trial data emerges to support increasingly wide use of SGLT2i. This consensus paper from EURECA-m and ERBP highlights the latest evidence and summarizes the guidelines for use of SGLT2i for cardiorenal protection focusing on benefits observed relevant to people with CKD.
引用
- Mark PB, Sarafidis P, Ekart R, et al. SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA. Nephrol Dial Transplant. 2023. PMID: 37230946. doi:10.1093/ndt/gfad112
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。